Panbela Holds Conference Call on August 15, 2022 to Release Second Quarter 2022 Financial Results

Panbela Therapeutics, Inc.

MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA)a clinical-stage company developing disruptive therapies for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on August 15, 2022 at 4:30 p.m. discuss the results of its second quarter ended in June. 30, 2022.

Conference call information

To participate in this event, dial approximately 5-10 minutes prior to the start of the call.

Date: August 15, 2022
Time: 4:30 p.m. Eastern Time
Toll Free: 888-506-0062; Access code: 429849
International: 973-528-0011; Access code: 429849
Webcast link:

Conference Call Replay Information

Toll Free: 877-481-4010
International: 919-882-2331
Proofreading code: 45649

About our pipeline

The pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention, and colon cancer. ovary. The combined development programs have a steady cadence of catalysts with programs ranging from preclinical studies to registration studies.


SBP-101 is a proprietary polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting the compound’s observed high affinity for pancreatic ductal adenocarcinoma and other tumors. The molecule has shown tumor growth inhibition signals in clinical studies of US and Australian patients with metastatic pancreatic cancer, demonstrating a median overall survival (OS) of 14.6 months, which is and an objective response rate (ORR) of 48%, both of which exceed what is typically seen with standard treatment of gemcitabine + nab-paclitaxel suggesting potential complementary activity with the standard FDA-approved chemotherapy regimen. In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression and peripheral neuropathy, which may be chemotherapy-related adverse events. Serious visual adverse events were assessed and patients with a history of retinopathy or at risk for retinal detachment will be excluded from future SBP-101 studies. The safety data and PMI profile observed in the clinical trial currently sponsored by Panbela support the continued evaluation of SBP-101 in a randomized clinical trial. For more information, please visit .


Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism of inhibiting polyamine synthesis and increasing polyamine export and catabolism. In a phase 3 clinical trial in patients with sporadic large bowel polyps, the combination prevented >90% of subsequent precancerous sporadic adenomas compared to placebo. Focusing on FAP patients with lower GI anatomy in the recent Phase 3 trial comparing Flynpovi to eflornithine monotherapy and sulindac monotherapy, FAP patients with lower GI anatomy (patients with intact colon, retained rectum, or surgical pouch), Flynpovi showed a statistically significant benefit over both single agents (p ≤ 0.02) in delaying lower GI surgical events for up to four years. The safety profile of Flynpovi did not differ significantly from that of single agents and supports the continued evaluation of Flynpovi for FAP.


CPP-1X (eflornithine) is being developed as a single-agent tablet or high-dose potent sachet for several indications, including gastric cancer prevention, treatment of neuroblastoma, and diabetes mellitus. type 1 of recent appearance. Preclinical studies as well as investigator-initiated Phase 1 or Phase 2 trials suggest that the CPP-1X treatment is well tolerated and has potential activity.

About Panbela

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapies for patients with urgent unmet medical needs. The Company’s main assets are SBP-101 and Flynpovi. Further information is available at The common stock of Panbela Therapeutics, Inc. is listed on the Nasdaq Stock Market LLC under the symbol PBLA.

Caution Regarding Forward-Looking Statements

This press release contains “forward-looking statements”, including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “believe”, “conceive”, “expect”, “feel”, “intend”, “may”, “plan”, “expect” and “will”. Examples of forward-looking statements include statements we make regarding the results of collaborations with third parties and future studies. All statements other than statements of historical fact are statements that should be considered forward-looking statements. Forward-looking statements are neither historical facts nor guarantees of future performance. Instead, they are based solely on our current beliefs, expectations and assumptions about the future of our business, Future plans and strategies, projections, anticipated events and trends, economic and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are beyond our control. Our actual results and financial condition may differ materially and adversely from forward-looking statements. Accordingly, you should not rely on any such forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those set forth in the forward-looking statements include, among others, the following: ( I ) our ability to obtain additional funds to conduct clinical trials; (ii) the progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to perform monitoring and reporting in our current clinical trial and to procure the active ingredient; (iv) our ability to demonstrate the safety and efficacy of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, European Union or other other international markets; (vi) the market acceptance and level of future sales of our product candidate SBP-101; (vii) cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in setting up reimbursement agreements with third-party payers; (ix) the effect of competing technological and market developments; (x) costs relating to the filing and prosecution of patent applications and the enforcement or defense of patent claims; and (xi) other factors as discussed in Part I, Item 1A under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risk disclosed in our Quarterly Reports on Form 10-Q and our current report. Reports on Form 8-K. Any forward-looking statement we make in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update publicly any forward-looking statement or the reasons why actual results would differ from those anticipated in such forward-looking statement, whether written or oral, whether Consequently new information, future developments or otherwise.

Contact information:

James Carbonara
R.I. Hayden
(646) 755-7412
[email protected]

Tammy Green
Panbela Therapeutics, Inc.
(952) 479-1196
[email protected]

Michael P. Boser